Soumitra Barik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Soumitra Barik has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Swarupa Mitra
Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 shared publications Abhinav Dewan
Department of Radiation Oncology Rajiv Gandhi Cancer Institute and Research Centre New Delhi India
1 shared publication- Abhinav Dewan
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India
1 shared publication Dushyant Kumar
Department of Molecular Biology Rajiv Gandhi Cancer Institute and Research Centre New Delhi India
1 shared publicationGayatri Vishwakarma
Department of Biostatistics Rajiv Gandhi Cancer Institute and Research Centre New Delhi India
1 shared publication- Gourav Kumar
Medical Physics Division & Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
1 shared publication
Latest Publications
- Open Access
- 30 September 2021
- Published by Korean Society of Medical Physics in Progress in Medical Physics
- Vol. 32 (3) , 70-81
Dosimetric Evaluation of Low-Dose Spillage Volumes for Head and Neck Cancer Using Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy Treatment Techniques
Gourav Kumar , Manindra Bhushan , Lalit Kumar , Vimal Kishore , Kothanda Raman , Pawan Kumar , Soumitra Barik , Sandeep Purohit. Progress in Medical Physics 2021;32:70-81. https://doi.org/10.14316/pmp.2021.32.3.70
- 30 September 2021
- Published by Korean Society of Medical Physics in Progress in Medical Physics
- Vol. 32 (3) , 70-81
Open AccessDosimetric Evaluation of Low-Dose Spillage Volumes for Head and Neck Cancer Using Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy Treatment Techniques
Gourav Kumar , Manindra Bhushan , Lalit Kumar , Vimal Kishore , Kothanda Raman , Pawan Kumar , Soumitra Barik , Sandeep Purohit. Progress in Medical Physics 2021;32:70-81. https://doi.org/10.14316/pmp.2021.32.3.70
- Open Access
- 3 March 2021
- Published by Wiley in Cancer Reports
- Vol. 4 (4) , e1348
To study the role of pre‐treatment microRNA (micro ribonucleic acid) expression as a predictor of response to chemoradiation in locally advanced carcinoma cervix
Background: Concurrent chemoradiotherapy followed by brachytherapy is the standard of care in locally advanced carcinoma cervix. There is no prognostic factor at present to predict the outcome of disease in locally advanced carcinoma cervix.Aim: Differential expression of microRNAs can be used as biomarkers to predict clinical response in locally advanced carcinoma cervix patients.Methods: Thirty‐two patients of locally advanced carcinoma cervix with International Federation of Gynecology and Obstetrics Stage IB‐IVA were enrolled from 2017 to 2018. Expression of microRNA‐9 5p, ‐31 3p, ‐100 5p, ‐125a 5p, ‐125b‐5p, and –200a 5p in formalin‐fixed paraffin embedded (FFPE) biopsied tissue were analyzed by real time quantitative reverse transcriptase polymerase chain reaction (RT qPCR). Pretreatment evaluation was done with clinical examination and MRI pelvis. All patients received concurrent chemoradiotherapy followed by brachytherapy. Patients were evaluated for the clinical response after 3 months of treatment, with clinical examination and MRI pelvis scan using RECIST 1.1 criteria. Patients with no residual disease were classified as Complete responders (CR) and with residual or progressive disease were classified as Nonresponders (NR). Results were statistically analyzed using Mann Whiney U test to examine significant difference between the expression of microRNA between complete responders (CR) and nonresponders (NR).Results: microRNA‐100 5p was upregulated in complete responders (CR) which showed a trend towards statistical significance (p value = 0.05).Conclusion: microRNA‐100 5p can serve as a potential molecular biomarker in predicting clinical response to chemoradiation in locally advanced Carcinoma cervix. Its role should be further investigated in a larger study population.
- 3 March 2021
- Published by Wiley in Cancer Reports
- Vol. 4 (4) , e1348
Open AccessTo study the role of pre‐treatment microRNA (micro ribonucleic acid) expression as a predictor of response to chemoradiation in locally advanced carcinoma cervix
Background: Concurrent chemoradiotherapy followed by brachytherapy is the standard of care in locally advanced carcinoma cervix. There is no prognostic factor at present to predict the outcome of disease in locally advanced carcinoma cervix.Aim: Differential expression of microRNAs can be used as biomarkers to predict clinical response in locally advanced carcinoma cervix patients.Methods: Thirty‐two patients of locally advanced carcinoma cervix with International Federation of Gynecology and Obstetrics Stage IB‐IVA were enrolled from 2017 to 2018. Expression of microRNA‐9 5p, ‐31 3p, ‐100 5p, ‐125a 5p, ‐125b‐5p, and –200a 5p in formalin‐fixed paraffin embedded (FFPE) biopsied tissue were analyzed by real time quantitative reverse transcriptase polymerase chain reaction (RT qPCR). Pretreatment evaluation was done with clinical examination and MRI pelvis. All patients received concurrent chemoradiotherapy followed by brachytherapy. Patients were evaluated for the clinical response after 3 months of treatment, with clinical examination and MRI pelvis scan using RECIST 1.1 criteria. Patients with no residual disease were classified as Complete responders (CR) and with residual or progressive disease were classified as Nonresponders (NR). Results were statistically analyzed using Mann Whiney U test to examine significant difference between the expression of microRNA between complete responders (CR) and nonresponders (NR).Results: microRNA‐100 5p was upregulated in complete responders (CR) which showed a trend towards statistical significance (p value = 0.05).Conclusion: microRNA‐100 5p can serve as a potential molecular biomarker in predicting clinical response to chemoradiation in locally advanced Carcinoma cervix. Its role should be further investigated in a larger study population.
- Open Access
- 20 November 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1117) , 20200686
Management of cervical cancer during the corona virus disease-19 (COVID-19) era
COVID-19 pandemic has had a catastrophic impact on the society, economy and heath-care system all over the globe with virus showing no signs of losing potency. As the situation appears to worsen, extra burden on other specialities like oncology seems to increase. Specific recommendations are necessary for management of cervical cancer in the current context. All concerned specialities must work together in the best interest of the patient. Attempts should be made at managing cervical cancer while limiting the viral spread among the patients and health-care workers without the loss of opportunity. Surgical intervention for early cervical cancer should be postponed or alternative modalities be considered. In a locally advanced disease, concurrent chemoradiation is the treatment of choice. In addition, the following under mentioned suggestions aim to discuss ways of minimizing infection spread, workload rationalization and providing guidance for management of cervical cancer in the presence of COVID-19 infection.
- 20 November 2020
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1117) , 20200686
Open AccessManagement of cervical cancer during the corona virus disease-19 (COVID-19) era
COVID-19 pandemic has had a catastrophic impact on the society, economy and heath-care system all over the globe with virus showing no signs of losing potency. As the situation appears to worsen, extra burden on other specialities like oncology seems to increase. Specific recommendations are necessary for management of cervical cancer in the current context. All concerned specialities must work together in the best interest of the patient. Attempts should be made at managing cervical cancer while limiting the viral spread among the patients and health-care workers without the loss of opportunity. Surgical intervention for early cervical cancer should be postponed or alternative modalities be considered. In a locally advanced disease, concurrent chemoradiation is the treatment of choice. In addition, the following under mentioned suggestions aim to discuss ways of minimizing infection spread, workload rationalization and providing guidance for management of cervical cancer in the presence of COVID-19 infection.